Molecular diagnostics company Myriad Genetics signed an agreement with PharmaMar, a company that specializes in developing marine-derived drugs, under which Myriad will conduct homologous ...

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved ...

The TSO 500 HRD research test aligns Myriad's gold standard MyChoice® CDx HRD technology with Illumina's pan-cancer test, TSO 500. The test was codeveloped with Merck (known as MSD outside the US and ...

Myriad Genetics, Inc. MYGN recently announced a collaboration with GSK plc GSK to advance in the field of genetic testing. The latest development is intended to improve access to homologous ...

Myriad Genetics, Inc. MYGN recently announced the expansion of a strategic partnership with Illumina Inc. ILMN to widen access to oncology homologous recombination deficiency (HRD) testing in the ...

BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, ...

Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).

Homologous recombination repair deficiency (HRD) is associated with response to poly-ADP-ribose polymerase inhibition (PARPi) therapy in advanced ovarian cancer. In combination with CGP, these ...

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...